

Disclosure of related party transactions for the half year ended 31st March, 2026		INR Cr
---	--	--

		Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period, when such transaction was
--	--	---

Sr No.	Investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.																							
	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments					Notes
													Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure						
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary														Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end usage)	
1	Cipla Limited		A S Kumar		Director of subsidiary	Any other transaction	Professional Fees	6.51	Approved			1.63	-	-										
2	Cipla Limited		AMPIN Energy Green Eleven Private Limited		Associate	Any other transaction	Electricity charges paid	12.00	Approved			6.45	-	-										
3	Cipla Limited		AMPIN Power Systems Private Limited		Associate	Any other transaction	Electricity charges paid	20.00	Approved			11.27	-	-										
4	Cipla Limited		Aspergen Inc.		Holding-Subsidiary	Any other transaction	Reimbursement Charges Received	10.00	Approved			5.29	-	-										
5	Cipla Limited		Aspergen Inc.		Holding-Subsidiary	Sale of goods or services		50.00	Approved			3.93	-	-										
6	Cipla Limited		Breathe Free Lanka (Private) Limited		Holding-Subsidiary	Any other transaction	Reimbursement Charges Received	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			-0.04	-	-										
7	Cipla Limited		Breathe Free Lanka (Private) Limited		Holding-Subsidiary	Sale of goods or services		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			102.13	-	-										
8	Cipla Limited		Cipla (China) Pharmaceutical Co., Ltd.		Holding-Subsidiary	Any other transaction	Reimbursement Charges Paid	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			1.82	-	-										
9	Cipla Limited		Cipla (China) Pharmaceutical Co., Ltd.		Holding-Subsidiary	Purchase of goods or services		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			4.33	-	-										
10	Cipla Limited		Cipla (EU) Limited		Holding-Subsidiary	Any other transaction	Reimbursement Charges Received	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			0.09	-	-										
11	Cipla Limited		Cipla (EU) Limited		Holding-Subsidiary	Purchase of goods or services		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			7.02	-	-										
12	Cipla Limited		Cipla (EU) Limited		Holding-Subsidiary	Sale of goods or services		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			87.16	-	-										
13	Cipla Limited		Cipla (Jiangsu) Pharmaceutical Co., Ltd.		Holding-Subsidiary	Any other transaction	Reimbursement Charges Paid	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			1.53	-	-										
14	Cipla Limited		Cipla (Jiangsu) Pharmaceutical Co., Ltd.		Holding-Subsidiary	Any other transaction	Reimbursement Charges Received	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			1.10	-	-										
15	Cipla Limited		Cipla (Jiangsu) Pharmaceutical Co., Ltd.		Holding-Subsidiary	Sale of fixed assets		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			2.55	-	-										
16	Cipla Limited		Cipla (Jiangsu) Pharmaceutical Co., Ltd.		Holding-Subsidiary	Sale of goods or services		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			1.84	-	-										
17	Cipla Limited		Cipla Australia Pty Limited		Holding-Subsidiary	Any other transaction	Reimbursement Charges Received	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			0.06	-	-										
18	Cipla Limited		Cipla Australia Pty Limited		Holding-Subsidiary	Any other transaction	Royalty Income	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			4.54	-	-										
19	Cipla Limited		Cipla Australia Pty Limited		Holding-Subsidiary	Purchase of goods or services		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			4.43	-	-										
20	Cipla Limited		Cipla Australia Pty Limited		Holding-Subsidiary	Sale of goods or services		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			4.73	-	-										
21	Cipla Limited		Cipla Brasil Importadora E Distribuidora De Medicamentos Ltda		Holding-Subsidiary	Any other transaction	Reimbursement Charges Paid	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			13.28	-	-										
22	Cipla Limited		Cipla Brasil Importadora E Distribuidora De Medicamentos Ltda		Holding-Subsidiary	Any other transaction	Reimbursement Charges Received	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			0.00	-	-										
23	Cipla Limited		Cipla Brasil Importadora E Distribuidora De Medicamentos Ltda		Holding-Subsidiary	Sale of goods or services		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			8.13	-	-										
24	Cipla Limited		Cipla Colombia SAS		Holding-Subsidiary	Any other transaction	Reimbursement Charges Received	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			0.02	-	-										
25	Cipla Limited		Cipla Colombia SAS		Holding-Subsidiary	Sale of goods or services		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			9.02	-	-										
26	Cipla Limited		Cipla Digital Health Limited		Holding-Subsidiary	Any other transaction	Reimbursement Charges Received	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			0.06	-	-										
27	Cipla Limited		Cipla Digital Health Limited		Holding-Subsidiary	Any other transaction	Royalty Income	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			0.00	-	-										
28	Cipla Limited		Cipla Digital Health Limited		Holding-Subsidiary	Purchase of goods or services		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			10.62	-	-										
29	Cipla Limited		Cipla Digital Health Limited		Holding-Subsidiary	Sale of goods or services		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			1.01	-	-										

Sr No.													Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.											
	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments					Notes
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end usage)	
61	Cipla Limited		Cipla Medpro South Africa Proprietary Limited		Holding-Subsidiary	Any other transaction	Royalty Income	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			29.67	-	-										
62	Cipla Limited		Cipla Medpro South Africa Proprietary Limited		Holding-Subsidiary	Interest received		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			28.99	-	-										
63	Cipla Limited		Cipla Pharma and Life Sciences Limited		Holding-Subsidiary	Any other transaction	Reimbursement Charges Received	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			3.25	-	-										
64	Cipla Limited		Cipla Pharma and Life Sciences Limited		Holding-Subsidiary	Any other transaction	Rent Received	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			0.67	-	-										
65	Cipla Limited		Cipla Pharma and Life Sciences Limited		Holding-Subsidiary	Any other transaction	Royalty Income	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			18.27	-	-										
66	Cipla Limited		Cipla Pharma and Life Sciences Limited		Holding-Subsidiary	Purchase of goods or services		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			1.06	-	-										
67	Cipla Limited		Cipla Pharma and Life Sciences Limited		Holding-Subsidiary	Sale of goods or services		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			142.04	-	-										
68	Cipla Limited		Cipla Pharmaceuticals Limited		Holding-Subsidiary	Any other transaction	Reimbursement Charges Paid	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			25.06	-	-										
69	Cipla Limited		Cipla Pharmaceuticals Limited		Holding-Subsidiary	Any other transaction	Reimbursement Charges Received	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			1.72	-	-										
70	Cipla Limited		Cipla Pharmaceuticals Limited		Holding-Subsidiary	Any other transaction	Rent Received	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			0.01	-	-										
71	Cipla Limited		Cipla Pharmaceuticals Limited		Holding-Subsidiary	Interest received		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			1.81	-	-										
72	Cipla Limited		Cipla Pharmaceuticals Limited		Holding-Subsidiary	Loan		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			90.00	-	-										
73	Cipla Limited		Cipla Pharmaceuticals Limited		Holding-Subsidiary	Purchase of fixed assets		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			2.84	-	-										
74	Cipla Limited		Cipla Pharmaceuticals Limited		Holding-Subsidiary	Purchase of goods or services		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			5.46	-	-										
75	Cipla Limited		Cipla Pharmaceuticals Limited		Holding-Subsidiary	Sale of fixed assets		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			1.11	-	-										
76	Cipla Limited		Cipla Pharmaceuticals Limited		Holding-Subsidiary	Sale of goods or services		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			6.38	-	-										
77	Cipla Limited		Cipla Select Proprietary Limited		Holding-Subsidiary	Sale of goods or services		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			41.53	-	-										
78	Cipla Limited		Cipla USA Inc.		Holding-Subsidiary	Any other transaction	Reimbursement Charges Paid	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			197.22	-	-										
79	Cipla Limited		Cipla USA Inc.		Holding-Subsidiary	Any other transaction	Reimbursement Charges Received	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			0.27	-	-										
80	Cipla Limited		Cipla USA Inc.		Holding-Subsidiary	Any other transaction	Royalty Income	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			-169.43	-	-										
81	Cipla Limited		Cipla USA Inc.		Holding-Subsidiary	Interest received		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			20.72	-	-										
82	Cipla Limited		Cipla USA Inc.		Holding-Subsidiary	Loan		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			328.87	-	-										
83	Cipla Limited		Cipla USA Inc.		Holding-Subsidiary	Purchase of goods or services		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			-0.36	-	-										
84	Cipla Limited		Cipla USA Inc.		Holding-Subsidiary	Sale of goods or services		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			648.92	-	-										
85	Cipla Limited		CiplaRna GmbH		Holding-Subsidiary	Any other transaction	Testing and Analysis Charges Paid	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			10.88	-	-										
86	Cipla Limited		Clean Max Auriga Power LLP		Associate	Any other transaction	Electricity charges paid	11.00	Approved			4.67	-	-										
87	Cipla Limited		Exelan Pharmaceuticals Inc.		Holding-Subsidiary	Any other transaction	Reimbursement Charges Paid	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			12.49	-	-										
88	Cipla Limited		Exelan Pharmaceuticals Inc.		Holding-Subsidiary	Any other transaction	Reimbursement Charges Received	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			0.07	-	-										

Sr No.														Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments					Notes
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end usage)	
89	Cipla Limited		Exelan Pharmaceuticals Inc.		Holding-Subsidiary	Any other transaction	Royalty Income	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			491.94	-	-										
90	Cipla Limited		Exelan Pharmaceuticals Inc.		Holding-Subsidiary	Sale of goods or services		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			16.50	-	-										
91	Cipla Limited		Geena Malhotra		Director of subsidiary	Any other transaction	Professional Fees	2.00	Approved			0.41	-	-										
92	Cipla Limited		GoApptiv Private Limited		Associate	Any other transaction	Reimbursement Charges Paid	15.00	Approved			2.88	-	-										
93	Cipla Limited		GoApptiv Private Limited		Associate	Purchase of goods or services		35.00	Approved			13.31	-	-										
94	Cipla Limited		GoApptiv Private Limited		Associate	Sale of goods or services		12.00	Approved			0.06	-	-										
95	Cipla Limited		Goldencross Pharma Limited		Holding-Subsidiary	Any other transaction	Processing charges paid	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			25.92	-	-										
96	Cipla Limited		Goldencross Pharma Limited		Holding-Subsidiary	Any other transaction	Reimbursement Charges Paid	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			7.53	-	-										
97	Cipla Limited		Goldencross Pharma Limited		Holding-Subsidiary	Any other transaction	Reimbursement Charges Received	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			0.36	-	-										
98	Cipla Limited		Goldencross Pharma Limited		Holding-Subsidiary	Purchase of goods or services		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			54.11	-	-										
99	Cipla Limited		Goldencross Pharma Limited		Holding-Subsidiary	Sale of fixed assets		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			0.43	-	-										
100	Cipla Limited		Goldencross Pharma Limited		Holding-Subsidiary	Sale of goods or services		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			16.48	-	-										
101	Cipla Limited		Icaltech Innovations Private Limited		Associate	Any other transaction	Reimbursement Charges Received	0.20	Approved			0.08	-	-										
102	Cipla Limited		Icaltech Innovations Private Limited		Associate	Purchase of goods or services		0.25	Approved			0.04	-	-										
103	Cipla Limited		Icaltech Innovations Private Limited		Associate	Sale of goods or services		0.30	Approved			0.08	-	-										
104	Cipla Limited		InvaGen Pharmaceuticals Inc.		Holding-Subsidiary	Any other transaction	Reimbursement Charges Received	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			1.70	-	-										
105	Cipla Limited		InvaGen Pharmaceuticals Inc.		Holding-Subsidiary	Purchase of goods or services		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			1.06	-	-										
106	Cipla Limited		InvaGen Pharmaceuticals Inc.		Holding-Subsidiary	Sale of goods or services		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			55.60	-	-										
107	Cipla Limited		Inzpera Healthsciences Limited		Holding-Subsidiary	Interest received		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			0.68	-	-										
108	Cipla Limited		Inzpera Healthsciences Limited		Holding-Subsidiary	Investment		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			9.13	-	-										
109	Cipla Limited		Inzpera Healthsciences Limited		Holding-Subsidiary	Loan		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			13.00	-	-										
110	Cipla Limited		Inzpera Healthsciences Limited		Holding-Subsidiary	Purchase of goods or services		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			19.40	-	-										
111	Cipla Limited		Inzpera Healthsciences Limited		Holding-Subsidiary	Sale of goods or services		0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			0.18	-	-										
112	Cipla Limited		Inzpera Healthsciences Limited		Holding-Subsidiary	Any other transaction	Loan converted into Equity	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			13.00	-	-										
113	Cipla Limited		Jay Precision Pharmaceuticals Private Limited		Holding-Subsidiary	Purchase of goods or services		220.00	Approved			71.75	-	-										
114	Cipla Limited		Jay Precision Products (India) Private Limited		Related party of a subsidiary	Any other transaction	Reimbursement Charges Paid	20.00	Approved			0.00	-	-										
115	Cipla Limited		Jay Precision Products (India) Private Limited		Related party of a subsidiary	Purchase of fixed assets		95.00	Approved			8.99	-	-										
116	Cipla Limited		Jay Precision Products (India) Private Limited		Related party of a subsidiary	Purchase of goods or services		5.00	Approved			0.44	-	-										
117	Cipla Limited		Kamil Hamied		Non-executive Director	Any other transaction	Sitting Fees/Commission and Other Benefits	1.32	Approved			1.32	-	-										
118	Cipla Limited		Medispray Laboratories Private Limited		Holding-Subsidiary	Any other transaction	Processing charges paid	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			33.27	-	-										
119	Cipla Limited		Medispray Laboratories Private Limited		Holding-Subsidiary	Any other transaction	Processing charges received	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			2.10	-	-										
120	Cipla Limited		Medispray Laboratories Private Limited		Holding-Subsidiary	Any other transaction	Reimbursement Charges Paid	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			0.16	-	-										

Sr No.															Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments					Notes	
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end usage)		
147	Cipla Limited		Stempeutics Research Private Limited		Associate	Any other transaction	Reimbursement Charges Paid	2.00	Approved			0.36	-	-											
148	Cipla Limited		Stempeutics Research Private Limited		Associate	Purchase of goods or services		20.50	Approved			5.00	-	-											
149	Cipla Limited		Synpure Labs India Private Limited		Related party of a subsidiary	Purchase of goods or services		1.00	Approved			0.02	-	-											
150	Cipla Limited		Veritas Legal		Firm in which director, manager or his relative is a partner	Purchase of goods or services		4.00	Approved			1.50	-	-											
151	Cipla Limited		Wellspring Healthcare Private Limited		Company in which a director or manager or his relative is a member or director	Purchase of goods or services		0.50	Approved			0.12	-	-										Additionally, during FY 25, transaction of INR 0.15 cr was entered.	
152	Cipla Limited		Y K Hamied		Non-executive Chairman	Any other transaction	Sitting Fees/Commission and Other Benefits	1.30	Approved			1.30	-	-											
153	Cipla Limited		Y K Hamied		Non-executive Chairman	Any other transaction	Rent Received	0.00	Approved			0.00	-	-											
154	Cipla Limited		Meditab Specialities Limited		Holding-Subsidiary	Any other transaction	Reimbursement Charges Paid	0.00	Transaction with wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			0.00	-	-											
155	Cipla Limited		Achira Labs Private Limited		Associate	Any other transaction	Trade and Other receivable	-	Not Applicable			-	0.03	0.03											
156	Cipla Limited		AMPIN Energy Green Eleven Private Limited		Associate	Any other transaction	Trade and Other payable	-	Not Applicable			-	2.00	2.77											
157	Cipla Limited		AMPIN Power Systems Private Limited		Associate	Any other transaction	Trade and Other payable	-	Not Applicable			-	0.00	2.84											
158	Cipla Limited		A S Kumar		Director of subsidiary	Any other transaction	Trade and Other payable	-	Not Applicable			-	0.49	1.32											
159	Cipla Limited		Aspergen Inc.		Holding-Subsidiary	Any other transaction	Trade and Other receivable	-	Not Applicable			-	4.61	12.28											
160	Cipla Limited		Breathe Free Lanka (Private) Limited		Holding-Subsidiary	Any other transaction	Trade and Other receivable	-	Not Applicable			-	64.68	37.45											
161	Cipla Limited		Cipla (China) Pharmaceutical Co., Ltd.		Holding-Subsidiary	Any other transaction	Trade and Other payable	-	Not Applicable			-	11.61	4.43											
162	Cipla Limited		Cipla (EU) Limited		Holding-Subsidiary	Any other transaction	Trade and Other receivable	-	Not Applicable			-	59.24	50.00											
163	Cipla Limited		Cipla (Jiangsu) Pharmaceutical Co., Ltd.		Holding-Subsidiary	Any other transaction	Trade and Other receivable	-	Not Applicable			-	-1.00	1.25											
164	Cipla Limited		Cipla Australia Pty Limited		Holding-Subsidiary	Any other transaction	Trade and Other receivable	-	Not Applicable			-	23.37	20.11											
165	Cipla Limited		Cipla Brasil Importadora E Distribuidora De Medicamentos Ltda		Holding-Subsidiary	Any other transaction	Trade and Other receivable	-	Not Applicable			-	24.14	30.81											
166	Cipla Limited		Cipla Colombia SAS		Holding-Subsidiary	Any other transaction	Trade and Other receivable	-	Not Applicable			-	46.94	33.05											
167	Cipla Limited		Cipla Digital Health Limited		Holding-Subsidiary	Any other transaction	Trade and Other payable	-	Not Applicable			-	3.62	3.82											
168	Cipla Limited		Cipla Europe NV		Holding-Subsidiary	Any other transaction	Trade and Other payable	-	Not Applicable			-	106.91	100.73											
169	Cipla Limited		Cipla Gulf FZ – LLC		Holding-Subsidiary	Any other transaction	Trade and Other payable	-	Not Applicable			-	-10.76	9.43											
170	Cipla Limited		Cipla Health Limited		Holding-Subsidiary	Any other transaction	Trade and Other receivable	-	Not Applicable			-	7.19	37.83											
171	Cipla Limited		Cipla Holding B.V.		Holding-Subsidiary	Any other transaction	Trade and Other payable	-	Not Applicable			-	14.37	19.56											
172	Cipla Limited		Cipla Kenya Limited		Holding-Subsidiary	Any other transaction	Trade and Other payable	-	Not Applicable			-	17.48	9.21											
173	Cipla Limited		Cipla Limited Employees Gratuity Fund		Post Employment Benefit Trust	Any other transaction	Payable to Gratuity Trust	-	Not Applicable			-	6.84	19.00											
174	Cipla Limited		Cipla Limited Employees Provident Fund		Post Employment Benefit Trust	Any other transaction	Payable to Provident Fund Trust	-	Not Applicable			-	17.39	28.99											
175	Cipla Limited		Cipla Malaysia Sdn. Bhd.		Holding-Subsidiary	Any other transaction	Trade and Other payable	-	Not Applicable			-	3.94	3.10											
176	Cipla Limited		Cipla Maroc S.A.		Holding-Subsidiary	Any other transaction	Trade and Other receivable	-	Not Applicable			-	27.97	47.90											
177	Cipla Limited		Cipla Medpro Manufacturing Proprietary Limited		Holding-Subsidiary	Any other transaction	Trade and Other receivable	-	Not Applicable			-	3.97	6.44											
178	Cipla Limited		Cipla Medpro South Africa Proprietary Limited		Holding-Subsidiary	Any other transaction	Trade and Other receivable	-	Not Applicable			-	19.68	26.97											
179	Cipla Limited		Cipla Medpro South Africa Proprietary Limited		Holding-Subsidiary	Loan		-	Not Applicable			-	616.50	552.25				Loan	250 bps higher than 3 months JIBAR rate	Repayable by 31st October 2029	Unsecured	Working Capital			
180	Cipla Limited		Cipla Pharma and Life Sciences Limited		Holding-Subsidiary	Any other transaction	Trade and Other receivable	-	Not Applicable			-	86.35	81.50											
181	Cipla Limited		Cipla Pharma and Life Sciences Limited		Holding-Subsidiary	Any other transaction	Capital Creditors	-	Not Applicable			-	0.00	0.63											
182	Cipla Limited		CiplaRna GmbH		Holding-Subsidiary	Any other transaction	Trade and Other payable	-	Not Applicable			-	3.32	6.37											
183	Cipla Limited		Cipla Select Proprietary Limited		Holding-Subsidiary	Any other transaction	Trade and Other receivable	-	Not Applicable			-	39.68	55.23											
184	Cipla Limited		Cipla USA Inc.		Holding-Subsidiary	Any other transaction	Trade and Other receivable	-	Not Applicable			-	2095.12	626.70											
185	Cipla Limited		Cipla USA Inc.		Holding-Subsidiary	Loan		-	Not Applicable			-	754.74	1138.02				Loan	Term SOFR + 150 bps	Repayable by 24th March 2028	Unsecured	Working Capital			
186	Cipla Limited		Clean Max Auriga Power LLP		Associate	Any other transaction	Trade and Other payable	-	Not Applicable			-	0.29	0.61											
187	Cipla Limited		Societe Marocaine De Cooperation Pharmaceutique (Cooper)		Related party of a subsidiary	Any other transaction	Trade and Other receivable	-	Not Applicable			-	18.83	10.16											
188	Cipla Limited		Exelan Pharmaceuticals Inc.		Holding-Subsidiary	Any other transaction	Trade and Other receivable	-	Not Applicable			-	164.91	349.71											
189	Cipla Limited		GoApptiv Private Limited		Associate	Any other transaction	Trade and Other payable	-	Not Applicable			-	7.35	1.28											
190	Cipla Limited		Goldencross Pharma Limited		Holding-Subsidiary	Any other transaction	Trade and Other payable	-	Not Applicable			-	27.32	15.43											
191	Cipla Limited		Icaltech Innovations Private Limited		Associate	Any other transaction	Trade and Other receivable	-	Not Applicable			-	0.03	0.13											
192	Cipla Limited		InvaGen Pharmaceuticals Inc.		Holding-Subsidiary	Any other transaction	Trade and Other receivable	-	Not applicable			-	-14.71	31.89											
193	Cipla Limited		Jay Precision Pharmaceuticals Private Limited		Holding-Subsidiary	Any other transaction	Trade and Other payable	-	Not applicable			-	19.25	18.22											
194	Cipla Limited		Jay Precision Products (India) Private Limited		Related party of a subsidiary	Any other transaction	Capital Advances	-	Not applicable			-	0.00	13.22											

Sr No.														Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.											
	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments					Notes	
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end usage)		
195	Cipla Limited		Kamil Hamied		Non-executive Director	Any other transaction	Commission and Other Benefits payable	-	Not applicable			-	1.25	1.53											
196	Cipla Limited		Medispray Laboratories Private Limited		Holding-Subsidiary	Any other transaction	Trade and Other payable	-	Not applicable			-	29.92	42.44											
197	Cipla Limited		Meditab Specialities Limited		Holding-Subsidiary	Any other transaction	Trade and Other payable	-	Not applicable			-	4.82	7.76											
198	Cipla Limited		Medpro Pharmaceutica Proprietary Limited		Holding-Subsidiary	Any other transaction	Trade and Other receivable	-	Not applicable			-	358.98	265.37											
199	Cipla Limited		Mexicip, S.A. de C.V.		Holding-Subsidiary	Any other transaction	Trade and Other payable	-	Not applicable			-	6.12	5.26											
200	Cipla Limited		Mirren Proprietary Limited		Holding-Subsidiary	Any other transaction	Trade and Other receivable	-	Not applicable			-	0.15	0.16											
201	Cipla Limited		Sekhmet Technologies Private Limited		Company in which a director or manager or his relative is a member or director	Any other transaction	Trade and Other payable	-	Not applicable			-	0.53	0.17											
202	Cipla Limited		Signet Excipients Private Limited		Related party of a subsidiary	Any other transaction	Trade and Other payable	-	Not applicable			-	14.22	9.23											
203	Cipla Limited		Sitec Labs Limited		Holding-Subsidiary	Any other transaction	Trade and Other payable	-	Not Applicable			-	5.52	10.49											
204	Cipla Limited		Sitec Labs Limited		Holding-Subsidiary	Loan		-	Not applicable			-	42.00	42.00				Loan	6.5%-7.5%	Repayable by 21st September 2027	Unsecured	Working Capital			
205	Cipla Limited		Stempeutics Research Private Limited		Associate	Any other transaction	Trade and Other payable	-	Not applicable			-	0.77	0.23											
206	Cipla Limited		Veritas Legal		Firm in which director, manager or his relative is a partner	Any other transaction	Trade and Other payable	-	Not applicable			-	0.75	0.68											
207	Cipla Limited		Wellspring Healthcare Private Limited		Company in which a director or manager or his relative is a member or director	Any other transaction	Trade and Other payable	-	Not applicable			-	0.06	0.07											
208	Cipla Limited		Y K Hamied		Non-executive Chairman	Any other transaction	Commission and Other Benefits payable	-	Not applicable			-	1.25	1.53											
209	Cipla Limited		Cipla Foundation		The entity over which KMP or relative of KMP are able to exercise significant influence	Any other transaction	Trade and Other receivable	-	Not applicable			-	0.00	5.09											
210	Cipla Limited		Cipla Pharmaceuticals Limited		Holding-Subsidiary	Any other transaction	Trade and Other payable	-	Not applicable			-	-0.08	24.74											
211	Cipla Limited		Cipla Pharmaceuticals Limited		Holding-Subsidiary	Loan		-	Not applicable			-	0.00	90.00				Loan	7.25%	Repayable by 6th November, 2030	Unsecured	Working Capital			
212	Cipla Limited		Inzpera Healthsciences Limited		Holding-Subsidiary	Any other transaction	Trade and Other receivable	-	Not applicable			-	0.00	0.72											
213	Cipla Limited		Inzpera Healthsciences Limited		Holding-Subsidiary	Loan		-	Not applicable			-	0.00	14.59				Loan	7.60%	Repayable by 30th August 2032	Unsecured	Working Capital			
214	Cipla Limited		Jay Precision Products (India) Private Limited		Related party of a subsidiary	Any other transaction	Trade and Other payable	-	Not applicable			-	-3.18	0.54											
215	Cipla Limited		Geena Malhotra		Director of subsidiary	Any other transaction	Trade and Other payable	-	Not applicable			-	0.33	0.00											
216	Cipla Limited		Synpure Labs India Private Limited		Related party of a subsidiary	Any other transaction	Trade and Other payable	-	Not applicable			-	-	0.00											
217	Cipla Digital Health Limited		Cipla Digital Health Limited Gratuity Trust		Post Employment Benefit Trust	Any other transaction	Contribution to Gratuity Fund	-	Not Applicable			0.35	-	-											
218	Jay Precision Pharmaceuticals Private Limited		Cipla Foundation		Related Party of the listed entity	Any other transaction	CSR Contribution	-	Not Applicable			0.58	-	-											
219	Jay Precision Pharmaceuticals Private Limited		Jay Precision Products (India) Private Limited		Private company in which a director/relative is a member/director	Purchase of fixed assets		40.00	Approved			3.62	-	-											
220	Jay Precision Pharmaceuticals Private Limited		Jay Precision Products (India) Private Limited		Private company in which a director/relative is a member/director	Any other transaction	Rent received	1.00	Approved			0.08	-	-											
221	Jay Precision Pharmaceuticals Private Limited		Jay Precision Products (India) Private Limited		Private company in which a director/relative is a member/director	Sale of goods or services		1.00	Approved			0.04	-	-											
222	Jay Precision Pharmaceuticals Private Limited		Jay Precision Products (India) Private Limited		Private company in which a director/relative is a member/director	Purchase of goods or services		2.00	Approved			0.08	-	-											
223	Jay Precision Pharmaceuticals Private Limited		Medispray Laboratories Private Limited		Subsidiaries	Sale of goods or services		45.00	Approved			4.47	-	-											
224	Jay Precision Pharmaceuticals Private Limited		Cipla Maroc SA		Subsidiaries	Sale of goods or services		2.00	Approved			0.43	-	-											
225	Jay Precision Pharmaceuticals Private Limited		Ampin Energy C&I Eighteen Private Limited		Associate	Any other transaction	Electricity charges paid	2.00	Approved			1.48	-	-											
226	Meditab Specialities Limited		Cipla Foundation		Related Party of the listed entity	Any other transaction	CSR Contribution	-	Not Applicable			0.09	-	-											
227	Meditab Specialities Limited		Signet Excipients Private Limited		Related Party of a Subsidiary	Purchase of goods or services		2.00	Approved			0.04	-	-											
228	Meditab Specialities Limited		Meditab Specialities Limited Employees Comprehensive Gratuity Scheme		Post employment benefit trust	Any other transaction	Contribution to Gratuity Fund	6.00	Approved			4.35	-	-											
229	Medispray Laboratories Private Limited		Cipla Maroc SA		Subsidiaries	Sale of goods or services		50.00	Approved			7.96	-	-											
230	Medispray Laboratories Private Limited		Meditab Specialities Limited		Subsidiaries	Sale of goods or services		-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			0.01	-	-											

Sr No.														Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.											
	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments					Notes	
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end usage)		
231	Medispray Laboratories Private Limited		Meditab Specialities Limited		Subsidiaries	Any other transaction	Reimbursement charges received	-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			0.07	-	-											
232	Medispray Laboratories Private Limited		Jay Precision Products (India) Private Limited		Related Party of a Subsidiary	Purchase of goods or services		10.00	Approved			0.13	-	-											
233	Medispray Laboratories Private Limited		Signet Excipients Private Limited		Related Party of a Subsidiary	Purchase of goods or services		5.00	Approved			0.72	-	-										Additionally, during FY 25, transaction of INR 1.85 cr was entered.	
234	Medispray Laboratories Private Limited		Cipla Foundation		Related Party of the listed entity	Any other transaction	CSR Contribution	-	Not Applicable			1.06	-	-											
235	Medispray Laboratories Private Limited		Medispray Laboratories Private Limited Employees Comprehensive Gratuity Scheme		Post employment benefit trust	Any other transaction	Contribution to Gratuity Fund	-	Not Applicable			20.25	-	-											
236	Goldencross Pharma Limited		Cipla Health Limited		Subsidiaries	Sale of goods or services		-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			4.02	-	-											
237	Goldencross Pharma Limited		Cipla Foundation		Related Party of the listed entity	Any other transaction	CSR Contribution	-	Not Applicable			0.09	-	-											
238	Sitec Labs Limited		Cipla USA Inc.		Subsidiaries	Any other transaction	Testing and Analysis Charges Received	-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			0.08	-	-											
239	Sitec Labs Limited		Medispray Laboratories Private Limited		Subsidiaries	Any other transaction	Testing and Analysis Charges Received	-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			0.03	-	-											
240	Sitec Labs Limited		Meditab Specialities Limited		Subsidiaries	Any other transaction	Testing and Analysis Charges Received	-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			-	-	-											
241	Sitec Labs Limited		InvaGen Pharmaceuticals Inc.		Subsidiaries	Any other transaction	Testing and Analysis Charges Received	-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			0.02	-	-											
242	Sitec Labs Limited		Cipla Foundation		Related Party of the listed entity	Any other transaction	CSR Contribution	-	Not Applicable			0.20	-	-											
243	Sitec Labs Limited		Sitec Labs Private Limited Employees Comprehensive Gratuity Scheme		Post employment benefit trust	Any other transaction	Contribution to Gratuity Fund	15.00	Approved			7.86	-	-											
244	Cipla Medpro Botswana Proprietary Limited		Medpro Pharmaceutica Proprietary Limited		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	-	-											
245	Cipla Health Limited		Cipla Pharma and Life Sciences Limited		Subsidiaries	Any other transaction	Reimbursement charges received	-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			7.67	-	-											
246	Cipla Health Limited		Cipla Foundation		Related Party of the listed entity	Any other transaction	CSR Contribution	-	Not Applicable			1.49	-	-											
247	Cipla Health Limited		Signet Excipients Private Limited		Private company in which a director/relative is a member/director	Purchase of goods or services		12.00	Approved			1.55	-	-										Additionally, during FY 25, transaction of INR 2.48 cr was entered.	
248	Cipla Health Limited		Cipla Health Limited Employees Gratuity Scheme		Post employment benefit trust	Any other transaction	Contribution to Gratuity Fund	-	Not Applicable			3.50	-	-											
249	Cipla Pharma and Life Sciences Limited		GoApptiv Private Limited		Associate of listed entity	Purchase of goods or services		2.00	Approved			-1.06	-	-											
250	Cipla Pharma and Life Sciences Limited		Cipla Foundation		Related Party of the listed entity	Any other transaction	CSR Contribution	-	Not Applicable			3.23	-	-											
251	Cipla Pharma and Life Sciences Limited		Cipla Pharma and Life Sciences Limited Employees Gratuity Fund		Post Employment Benefit Trust	Any other transaction	Contribution to Gratuity Fund	-	Not Applicable			4.09	-	-											
252	Meditab Holdings Limited		Cipla Kenya Limited		Subsidiaries	Interest received		-	Transaction between wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			0.50	-	-											
253	Cipla USA Inc.		InvaGen Pharmaceuticals Inc.		Subsidiaries	Any other transaction	Reimbursement charges received	-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			5.82	-	-											
254	Cipla USA Inc.		InvaGen Pharmaceuticals Inc.		Subsidiaries	Sale of goods or services		-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			0.64	-	-											
255	Cipla USA Inc.		Exelan Pharmaceuticals Inc.		Subsidiaries	Any other transaction	Reimbursement charges received	-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			1.18	-	-											
256	Cipla USA Inc.		Aspergen Inc.		Subsidiaries	Sale of goods or services		50.00	Approved			0.53	-	-											
257	Cipla USA Inc.		Aspergen Inc.		Subsidiaries	Any other transaction	Reimbursement charges received	5.00	Approved			0.57	-	-											
258	Actor Pharma Proprietary Limited		Cipla Select Proprietary Limited		Subsidiaries	Sale of goods or services		-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			2.74	-	-											
259	Actor Pharma Proprietary Limited		Medpro Pharmaceutica Proprietary Limited		Subsidiaries	Sale of goods or services		-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			11.83	-	-											
260	Cipla-Medpro Distribution Centre Proprietary Limited		Medpro Pharmaceutica Proprietary Limited		Subsidiaries	Any other transaction	Reimbursement charges received	-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			45.31	-	-											
261	Cipla Medpro Manufacturing Proprietary Limited		Medpro Pharmaceutica Proprietary Limited		Subsidiaries	Sale of goods or services		600.00	Approved			253.31	-	-											
262	Cipla Medpro Manufacturing Proprietary Limited		Cipla Select Proprietary Limited		Subsidiaries	Sale of goods or services		20.00	Approved			9.01	-	-											

Sr No.														Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.											
	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments					Details of the loans, inter-corporate deposits, advances or investments					Notes
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end usage)		
263	Cipla Medpro Manufacturing Proprietary Limited		The Cipla Foundation, South Africa		Entities over which the company is able to exercise significant influence/Control	Any other transaction	Donation paid	15.00	Approved			4.92	-	-											
264	Cipla Medpro South Africa Proprietary Limited		Cipla Medpro Manufacturing Proprietary Limited		Subsidiaries	Any other transaction	Reimbursement charges received	20.00	Approved			0.83	-	-											
265	Cipla Medpro South Africa Proprietary Limited		Cipla Medpro Manufacturing Proprietary Limited		Subsidiaries	Any other transaction	Royalty Income	50.00	Approved			23.07	-	-											
266	Cipla Medpro South Africa Proprietary Limited		Brandmed Proprietary Limited		Associate	Interest received		-	Not Applicable			1.00	-	-											
267	Cipla Medpro South Africa Proprietary Limited		Medpro Pharmaceutica Proprietary Limited		Subsidiaries	Interest received		-	Transaction between wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			17.91	-	-											
268	Cipla Medpro South Africa Proprietary Limited		Medpro Pharmaceutica Proprietary Limited		Subsidiaries	Any other transaction	Loan given	-	Transaction between wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			54.04	-	-											
269	Cipla Select Proprietary Limited		Medpro Pharmaceutica Proprietary Limited		Subsidiaries	Sale of goods or services		-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			1.06	-	-											
270	Cipla-Medpro Proprietary Limited		Medpro Pharmaceutica Proprietary Limited		Subsidiaries	Any other transaction	Royalty Income	-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			12.72	-	-											
271	Cipla-Medpro Proprietary Limited		Cipla Select Proprietary Limited		Subsidiaries	Any other transaction	Royalty Income	-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			1.21	-	-											
272	Medpro Pharmaceutica Proprietary Limited		Cipla Select Proprietary Limited		Subsidiaries	Sale of goods or services		-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			1.56	-	-											
273	Medpro Pharmaceutica Proprietary Limited		Cipla Kenya Limited		Subsidiaries	Sale of goods or services		-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			0.29	-	-											
274	Medpro Pharmaceutica Proprietary Limited		Cipla-Medpro Distribution Centre Proprietary Limited		Subsidiaries	Any other transaction	Reimbursement charges received	-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			6.30	-	-											
275	Medpro Pharmaceutica Proprietary Limited		The Cipla Foundation, South Africa		Entities over which the company is able to exercise significant influence/Control	Any other transaction	Donation paid	15.00	Approved			0.40	-	-											
276	Medpro Pharmaceutica Proprietary Limited		Cipla Select Proprietary Limited		Subsidiaries	Any other transaction	Reimbursement charges received	-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			3.10	-	-											
277	Medpro Pharmaceutica Proprietary Limited		Cipla Select Proprietary Limited		Subsidiaries	Any other transaction	Reimbursement charges received	-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			23.15	-	-											
278	Medpro Pharmaceutica Proprietary Limited		Cipla Medpro South Africa Proprietary Limited		Subsidiaries	Any other transaction	Reimbursement charges received	-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			7.75	-	-											
279	Medpro Pharmaceutica Proprietary Limited		Cipla Medpro Manufacturing Proprietary Limited		Subsidiaries	Any other transaction	Reimbursement charges received	50.00	Approved			18.78	-	-											
280	Medpro Pharmaceutica Proprietary Limited		Cipla Medpro Manufacturing Proprietary Limited		Subsidiaries	Any other transaction	Reimbursement charges paid	85.81	Approved			43.87	-	-											
281	Medpro Pharmaceutica Proprietary Limited		Mirren Proprietary Limited		Subsidiaries	Any other transaction	Reimbursement charges received	-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			0.19	-	-											
282	Medpro Pharmaceutica Proprietary Limited		Cipla Kenya Limited		Subsidiaries	Any other transaction	Reimbursement charges received	-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			0.23	-	-											
283	Medpro Pharmaceutica Proprietary Limited		Cipla-Medpro Proprietary Limited		Subsidiaries	Any other transaction	Reimbursement charges received	-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			3.30	-	-											
284	Mirren Proprietary Limited		Medpro Pharmaceutica Proprietary Limited		Subsidiaries	Sale of goods or services		-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			66.47	-	-											
285	Mirren Proprietary Limited		Cipla Medpro Manufacturing Proprietary Limited		Subsidiaries	Sale of goods or services		-	Not Applicable			0.04	-	-											
286	Meditab Holdings Limited		Cipla Kenya Limited		Subsidiaries	Any other transaction	Repayment of loan received	-	Transaction between wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			9.03	-	-											
287	InvaGen Pharmaceuticals Inc.		Cipla USA Inc.		Subsidiaries	Sale of goods or services		-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			80.12	-	-											
288	InvaGen Pharmaceuticals Inc.		Cipla USA Inc.		Subsidiaries	Sale of goods or services		-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			171.84	-	-											
289	InvaGen Pharmaceuticals Inc.		Cipla USA Inc.		Subsidiaries	Any other transaction	Reimbursement charges received	-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			50.73	-	-											
290	InvaGen Pharmaceuticals Inc.		Exelan Pharmaceuticals Inc.		Subsidiaries	Sale of goods or services		-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			132.67	-	-											
291	InvaGen Pharmaceuticals Inc.		Exelan Pharmaceuticals Inc.		Subsidiaries	Any other transaction	Reimbursement charges received	-	Transaction between wholly owned subsidiaries; Audit committee approval is not required as per applicable laws.			80.35	-	-											

Sr No.														Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments					Notes
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end usage)	
321	Goldencross Pharma Limited		Goldencross Pharma Limited Employees Group Gratuity Fund		Post Employment Benefit Trust	Any other transaction	Contribution to Gratuity Fund	-	Not Applicable			7.16	-	-										
322	Cipla (EU) Limited		Cipla Australia Pty Limited		Subsidiaries	Any other transaction	Repayment of loan received	-	Transaction between wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			15.32	-	-										
323	Cipla (EU) Limited		Cipla Gulf FZ-LLC		Subsidiaries	Any other transaction	Repayment of loan received	-	Transaction between wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			18.05	-	-										
324	Cipla (EU) Limited		CiplaRna GmbH		Subsidiaries	Investment		-	Transaction between wholly owned subsidiary; Audit committee approval is not required as per applicable laws.			4.52	-	-										
325	Cipla Pharmaceuticals Limited		Cipla Foundation		Related Party of the listed entity	Any other transaction	CER Contribution	5.60	Approved			1.71	-	-										
326	Cipla Digital Health Limited		Cipla Digital Health Limited Gratuity Trust		Post Employment Benefit Trust	Any other transaction	Receivable from Gratuity Trust	-	Not Applicable			-	-0.15	0.05										
327	Jay Precision Pharmaceuticals Private Limited		Jay Precision Products (India) Private Limited		Private company in which a director/relative is a member/director	Any other transaction	Capital Advance	-	Not Applicable			-	-4.32	3.99										
328	Jay Precision Pharmaceuticals Private Limited		Jay Precision Products (India) Private Limited		Private company in which a director/relative is a member/director	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	0.01	0.05										
329	Jay Precision Pharmaceuticals Private Limited		Medispray Laboratories Private Limited		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	1.41	0.49										
330	Jay Precision Pharmaceuticals Private Limited		Cipla Maroc SA		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	0.21	0.45										
331	Jay Precision Pharmaceuticals Private Limited		Jay Precision Pharmaceuticals Employees Group Gratuity Trust		Post employment benefit trust	Any other transaction	Payable to Gratuity Trust	-	Not Applicable			-	0.19	0.43										
332	Meditab Specialities Limited		Signet Excipients Private Limited		Related Party of a Subsidiary	Any other transaction	Trade and Other Payable	-	Not Applicable			-	0.03	0.00										
333	Meditab Specialities Limited		Meditab Specialities Limited Employees Comprehensive Gratuity Scheme		Post employment benefit trust	Any other transaction	Payable to Gratuity Trust	-	Not Applicable			-	2.47	0.24										
334	Medispray Laboratories Private Limited		Cipla Maroc SA		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	15.91	8.38										
335	Medispray Laboratories Private Limited		Meditab Specialities Limited		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	0.01	0.03										
336	Medispray Laboratories Private Limited		Jay Precision Products (India) Private Limited		Related Party of a Subsidiary	Any other transaction	Trade and Other Payable	-	Not Applicable			-	0.13	0.00										
337	Medispray Laboratories Private Limited		Jay Precision Products (India) Private Limited		Related Party of a Subsidiary	Any other transaction	Capital Advance	-	Not Applicable			-	-	20.06										
338	Medispray Laboratories Private Limited		Signet Excipients Private Limited		Related Party of a Subsidiary	Any other transaction	Trade and Other Payable	-	Not Applicable			-	0.49	0.29										
339	Medispray Laboratories Private Limited		Medispray Laboratories Private Limited Employees Comprehensive Gratuity Scheme		Post employment benefit trust	Any other transaction	Payable to Gratuity Trust	-	Not Applicable			-	10.91	1.23										
340	Goldencross Pharma Limited		Jay Precision Pharmaceuticals Private Limited		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	0.28	0.00										
341	Goldencross Pharma Limited		Cipla Health Limited		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	0.95	0.00										
342	Goldencross Pharma Limited		Goldencross Pharma Limited Employees Group Gratuity Fund		Post Employment Benefit Trust	Any other transaction	Payable to Gratuity Trust	-	Not Applicable			-	3.53	0.16										
343	Sitec Labs Limited		Cipla USA Inc.		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	0.06	0.03										
344	Sitec Labs Limited		Medispray Laboratories Private Limited		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	0.05	0.03										
345	Sitec Labs Limited		Meditab Specialities Limited		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	-	0.00										
346	Sitec Labs Limited		Cipla Health Limited		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	-	0.00										
347	Sitec Labs Limited		InvaGen Pharmaceuticals Inc.		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	0.36	0.00										
348	Sitec Labs Limited		Sitec Labs Private Limited Employees Comprehensive Gratuity Scheme		Post employment benefit trust	Any other transaction	Payable to Gratuity Trust	-	Not Applicable			-	7.07	6.36										
349	Cipla Health Limited		Cipla Pharma and Life Sciences Limited		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	1.69	9.01										
350	Cipla Health Limited		Signet Excipients Private Limited		Private company in which a director/relative is a member/director	Any other transaction	Trade and Other Payable	-	Not Applicable			-	2.90	0.00										
351	Cipla Health Limited		Cipla Health Limited Employees Gratuity Scheme		Post employment benefit trust	Any other transaction	Payable to Gratuity Trust	-	Not Applicable			-	1.46	2.60										
352	Cipla Pharma and Life Sciences Limited		GoApptiv Private Limited		Associate of listed entity	Any other transaction	Trade and Other Payable	-	Not Applicable			-	1.56	0.18										
353	Cipla Pharma and Life Sciences Limited		Cipla Pharma and Life Sciences Limited Employees Gratuity Fund		Post Employment Benefit Trust	Any other transaction	Receivable from Gratuity Trust	-	Not Applicable			-	-2.11	0.51										
354	Actor Pharma Proprietary Limited		Medpro Pharmaceutica Proprietary Limited		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	23.61	17.53										
355	Actor Pharma Proprietary Limited		Cipla Select Proprietary Limited		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	22.04	23.26										
356	Cipla-Medpro Distribution Centre Proprietary Limited		Cipla Kenya Limited		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	0.27	0.00										

Sr No.															Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.										
	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments					Notes	
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end usage)		
357	Cipla Medpro Manufacturing Proprietary Limited		Cipla Empowerment Trust		Entities over which the company is able to exercise significant influence/Control	Any other transaction	Advance	-	Not Applicable			-	-	0.00											
358	Cipla Medpro Manufacturing Proprietary Limited		Cipla Empowerment Trust		Entities over which the company is able to exercise significant influence/Control	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	-	0.08											
359	Cipla Medpro Manufacturing Proprietary Limited		Medpro Pharmaceutica Proprietary Limited		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	315.27	480.62											
360	Cipla Medpro Manufacturing Proprietary Limited		Cipla Select Proprietary Limited		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	4.69	17.29											
361	Cipla Medpro South Africa Proprietary Limited		Brandmed Proprietary Limited		Associate	Loan		-	Not Applicable			-	23.01	25.75					Loan	South African prime rate less 1.75%	Repayment to start from 31 March 2025 to 31 March 2028	Unsecured	Working Capital		
362	Cipla Medpro South Africa Proprietary Limited		Cipla-Medpro Proprietary Limited		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	2.21	0.00											
363	Cipla Medpro South Africa Proprietary Limited		Cipla Medpro Manufacturing Proprietary Limited		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	13.22	41.54											
364	Cipla Medpro South Africa Proprietary Limited		Medpro Pharmaceutica Proprietary Limited		Subsidiaries	Loan		-	Not Applicable			-	400.73	485.98					Loan	250 bps higher than 3 months JIBAR rate capped at the prime lending rate in South Africa	Repayment starts with 31 March 2026 to Oct 2029	Unsecured	Working Capital		
365	Cipla Select Proprietary Limited		Medpro Pharmaceutica Proprietary Limited		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	0.03	0.69											
366	Cipla-Medpro Proprietary Limited		Cipla Select Proprietary Limited		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	2.69	1.94											
367	Medpro Pharmaceutica Proprietary Limited		Cipla Medpro Manufacturing Proprietary Limited		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	176.10	573.04											
368	Medpro Pharmaceutica Proprietary Limited		Cipla Medpro Manufacturing Proprietary Limited		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	1.62	1.74											
369	Medpro Pharmaceutica Proprietary Limited		Cipla Medpro South Africa Proprietary Limited		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	243.82	371.88											
370	Medpro Pharmaceutica Proprietary Limited		Cipla Select Proprietary Limited		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	0.70	29.08											
371	Medpro Pharmaceutica Proprietary Limited		Cipla Select Proprietary Limited		Subsidiaries	Any other transaction	Trade and Other Payables	-	Not Applicable			-	34.91	18.28											
372	Medpro Pharmaceutica Proprietary Limited		Cipla Kenya Limited		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	28.60	31.27											
373	Medpro Pharmaceutica Proprietary Limited		Cipla-Medpro Distribution Centre Proprietary Limited		Subsidiaries	Any other transaction	Trade and Other Payables	-	Not Applicable			-	10.09	10.82											
374	Medpro Pharmaceutica Proprietary Limited		Cipla-Medpro Proprietary Limited		Subsidiaries	Any other transaction	Trade and Other Payable	-	Not Applicable			-	1.22	1.93											
375	Medpro Pharmaceutica Proprietary Limited		Mirren Proprietary Limited		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	57.19	59.75											
376	Mirren Proprietary Limited		Cipla Medpro Manufacturing Proprietary Limited		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	1.04	1.16											
377	Mirren Proprietary Limited		Medpro Pharmaceutica Proprietary Limited		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	15.64	31.37											
378	Meditab Holdings Limited		Cipla Kenya Limited		Subsidiaries	Loan		-	Not Applicable			-	24.00	16.55					Loan	6.00%	Repayable on Demand	Unsecured	Working Capital		
379	Cipla USA Inc.		Exelan Pharmaceuticals Inc.		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	0.01	0.00											
380	Cipla USA Inc.		Aspergen Inc.		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	0.42	1.44											
381	Cipla USA Inc.		Cipla Therapeutics Inc.		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	1.48	0.00											
382	InvaGen Pharmaceuticals Inc.		Cipla USA Inc.		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	107.03	7.21											
383	InvaGen Pharmaceuticals Inc.		Exelan Pharmaceuticals Inc.		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	39.35	42.95											
384	InvaGen Pharmaceuticals Inc.		Cipla Therapeutics Inc.		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	-	0.02											
385	Aspergen Inc.		Kernwell Biopharma Private Limited		Private company in which a director/relative is a member/director	Any other transaction	Trade and Other Payable	-	Not Applicable			-	27.66	77.52											
386	Cipla Maroc SA		Societe Marocaine De Cooperation Pharmaceutique (Cooper)		Investing Company	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	70.69	73.26											
387	Cipla Maroc SA		Societe Marocaine De Cooperation Pharmaceutique (Cooper)		Investing Company	Any other transaction	Interest Payable	-	Not Applicable			-	0.64	0.62											
388	Cipla Australia Pty Limited		Cipla Gulf FZ-LLC		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	8.59	9.51											
389	Cipla Europe NV		CiplaRna GmbH		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	1.79	10.02											
390	Cipla (EU) Limited		Cipla Europe NV		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	26.03	5.07											
391	Cipla (EU) Limited		Cipla Gulf FZ-LLC		Subsidiaries	Loan		-	Not Applicable			-	17.76	0.00				Loan	5.50%		5	Unsecured	Working Capital		
392	Cipla (EU) Limited		Cipla Australia Pty Limited		Subsidiaries	Any other transaction	Interest receivable	-	Not Applicable			-	0.61	0.00											
393	Cipla (EU) Limited		Cipla Australia Pty Limited		Subsidiaries	Loan		-	Not Applicable			-	15.06	0.00				Loan	2.80%	4 to 6		Unsecured	Working Capital		
394	Cipla (EU) Limited		Cipla (Jiangsu) Pharmaceutical Co., Ltd.		Subsidiaries	Loan		-	Not Applicable			-	110.99	118.54				Loan	4% to 6%		1	Unsecured	Working Capital		
395	Cipla (EU) Limited		Cipla (Jiangsu) Pharmaceutical Co., Ltd.		Subsidiaries	Any other transaction	Interest Receivable	-	Not Applicable			-	19.59	24.45											
396	Cipla (EU) Limited		Mexicip, S.A. de C.V.		Subsidiaries	Loan		-	Not Applicable			-	5.77	3.79				Loan	8.00%		2	Unsecured	Working Capital		
397	Cipla (EU) Limited		Cipla Maroc SA		Subsidiaries	Any other transaction	Dividend Receivable	-	Not Applicable			-	16.31	0.00											
398	Cipla Holding B.V.		Cipla Europe NV		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	9.85	4.41											

Sr No.	Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.																						
	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other related party transaction	Value of the related party transaction as approved by the audit committee	Remarks on approval by audit committee	Value of the related party transaction ratified by the audit committee	Date of Audit Committee Meeting where the ratification was approved	Value of transaction during the reporting period	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments				Notes
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary								Opening balance	Closing balance	Nature of indebtedness (loan/ issuance of debt/ any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan/ advance/ intercorporate deposit/ investment)	Interest Rate (%)	Tenure	Secured/ unsecured	
399	Cipla Holding B.V.		Cipla (EU) Limited		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	11.09	4.90									
400	Cipla Gulf FZ-LLC		Cipla Brasil Importadora E Distribuidora De Medicamentos Ltda		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	11.47	2.24									
401	Cipla (Jiangsu) Pharmaceutical Co., Ltd.		Cipla (EU) Limited		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	0.23	0.00									
402	Cipla (Jiangsu) Pharmaceutical Co., Ltd.		Cipla USA Inc.		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	52.21	96.06									
403	Cipla (China) Pharmaceutical Co., Ltd		Cipla (Jiangsu) Pharmaceutical Co., Ltd.		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	1.09	0.60									
404	Cipla (China) Pharmaceutical Co., Ltd		Shanghai Sage Business Consulting Co Ltd		Entity related to KMP	Any other transaction	Trade and Other Payable	-	Not Applicable			-	0.57	0.61									
405	Cipla (EU) Limited		CiplaRna GmbH		Subsidiaries	Any other transaction	Trade and Other Receivables	-	Not Applicable			-	0.12	0.13									

Notes:

2 The value of the related party transaction denotes the amount approved by the Audit Committee/ Board of Directors of Cipla Limited, as applicable, for financial year 2025-26.

3 Amount mentioned as "0.00" denotes value less than ₹ 50,000.